These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23600404)

  • 1. Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Chen IJ
    Int J Urol; 2013 Dec; 20(12):1227. PubMed ID: 23600404
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Murtola TJ
    Int J Urol; 2013 Dec; 20(12):1227-8. PubMed ID: 23600459
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
    Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Repositioning of the α
    Florent R; Poulain L; N'Diaye M
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
    Takeda M; Homma Y; Araki I; Kakizaki H; Yamanishi T; Yokota T; Gotoh M; Igawa Y; Seki N; Takei M; Yoshida M; Sugaya K; Nishizawa O;
    BJU Int; 2011 Jul; 108(1):100-7. PubMed ID: 21062392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
    Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
    Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
    Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
    Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Funahashi Y
    Int J Urol; 2013 May; 20(5):521. PubMed ID: 23131001
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment from Dr Ishizuka to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Ishizuka O
    Int J Urol; 2013 May; 20(5):520. PubMed ID: 23078593
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment from Dr Park to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Park WH
    Int J Urol; 2013 May; 20(5):519-20. PubMed ID: 23078577
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
    J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo.
    Huang JJ; Cai Y; Yi YZ; Huang MY; Zhu L; He F; Liu XW; Huang BY; Yuan M
    Eur J Pharmacol; 2016 Nov; 791():473-481. PubMed ID: 27615445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume.
    Yokoyama O; Aoki Y; Tsujimura A; Takao T; Namiki M; Okuyama A
    World J Urol; 2011 Apr; 29(2):233-8. PubMed ID: 20387069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
    Iwamoto Y; Ishii K; Kanda H; Kato M; Miki M; Kajiwara S; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):933-939. PubMed ID: 28243746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
    Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
    J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.
    Björnebo L; Razdan S; Discacciati A; Palsdottir T; Aly M; Nordström T; Eklund M; Lundon D; Grönberg H; Tewari A; Wiklund P; Kyprianou N; Lantz A
    J Natl Cancer Inst; 2024 Sep; 116(9):1459-1465. PubMed ID: 38718219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking.
    Masachika E; Kanno T; Nakano T; Gotoh A; Nishizaki T
    Anticancer Res; 2013 Mar; 33(3):887-94. PubMed ID: 23482758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.